(Q41360368)

29 September 2017

1 reference

title

New antipsychotic medications: what advantages do they offer? (English)

1 reference

29 September 2017

1

1 reference

29 September 2017

language of work or name

English

0 references

publication date

1 February 1997

1 reference

29 September 2017

published in

Postgraduate Medicine

1 reference

29 September 2017

volume

101

1 reference

29 September 2017

issue

2

1 reference

29 September 2017

page(s)

207-10, 213-4

1 reference

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

29 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3810%2FPGM.1997.02.166

Clozapine-induced agranulocytosis. Incidence and risk factors in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.1997.02.166

Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.1997.02.166

Clozapine — A Novel Antipsychotic Agent

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.1997.02.166

Risperidone in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.1997.02.166

Patient response and resource management: another view of clozapine treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.1997.02.166

21 January 2018

Identifiers

DOI

10.3810/PGM.1997.02.166

1 reference

29 September 2017

1 reference